Cambrex Company Profile

12:56 EST 18th November 2017 | BioPortfolio

Cambrex Corporation (NYSE:CBM) provides products and services to accelerate the development and commercialization of branded and generic small molecule therapeutics. Cambrex supports its customers worldwide with R&D and cGMP manufacturing facilities in the US and Europe, an excellent regulatory compliance record and strong expertise in various chemical technologies. Pharmaceutical Products & Services Cambrex has built a comprehensive platform of chemical technologies for the synthesis of small molecule active pharmaceutical ingredients (APIs). We have extensive experience developing drug substances from early stage through clinical development, up to launch and commercial supply – from grams to tons. Cambrex has a broad range of services, which include: route selection, process development, analytical development, process scale-up, safety assessments and optimization. Our core technologies and offerings include: Highly Potent & Cytotoxic Compounds, High Energy, Hydrogenation, Biocatalysis/Biotransformation, Chiral Synthesis, Controlled Substances, Nitration and Polymeric Drug Delivery, including Taste Masking. Generic APIs For generic drug companies, Cambrex supplies more than 70 APIs (including controlled substances) for pain management, cardiovascular, gastrointestinal, central nervous system, endocrine and respiratory indications. Cambrex manufactures these products using complex chemistry and technical expertise while maintaining its long-standing reputation of quality and reliability. We work with generic drug companies well in advance of drug patent expiration, provide a non-infringing process and file a Drug Master File (DMF) for the generic active pharmaceutical ingredients.


New Jersey
United States of America


Phone: 201 804 3000

News Articles [47 Associated News Articles listed on BioPortfolio]

Cambrex investing $24m in API manufacturing capabilities

Cambrex Corporation is investing $24m in a new facility to manufacture highly potent APIs (HPAPIs).

Cambrex sees Q2 revs and earnings rise, confirms interest in takeovers

Cambrex Corporation says higher demand for APIs for controlled substances and branded drugs drove Q2 growth and confirms it is on the lookout for acquisitions. 

Cambrex adds new development and analytical equipment in Italy

Cambrex Corporation has announced a new investment in its research and development (R&D) and manufacturing capabilities at its site in Paullo, Milan, Italy.

Cambrex expands Swedish manufacturing facility

Manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), Cambrex has installed a new, large scale manufacturing capacity at its cGMP facility in Karlskoga, Sweden...

Cambrex adds potent API capacity citing growing generic opportunities

Cambrex Corporation has announce plans to start making high potency APIs at its plant in Milan, Italy citing impending patent losses for small molecule drugs as an opportunity.

Cambrex adding $3.2m analytical lab at NC facility

Cambrex Corporation is adding a new $3.2m, 11,000 square foot analytical laboratory to its High Point, NC-based facility.

Cambrex Expands Charles City API Plant

Cambrex Corporation, a US manufacturer of active pharmaceutical ingredients (APIs) has announced another expansion to boost its global network. This latest project will see an investment of $24 millio...

Cambrex Expanding Generic API Capabilities In Europe

NewsCambrex invests in generic API development and manufacturing capabilities at its Milan site. The investments include a new hydrogenator and centrifuge for increased flexibility and capacity within...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]

Cambrex Corporation

Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including APIs, advanced intermediates, enhanced drug delivery, and other prod...


Cambrex Corporation (NYSE:CBM) provides products and services to accelerate the development and commercialization of branded and generic small molecule therapeutics. Cambrex supports its customers wor...

More Information about "Cambrex" on BioPortfolio

We have published hundreds of Cambrex news stories on BioPortfolio along with dozens of Cambrex Clinical Trials and PubMed Articles about Cambrex for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cambrex Companies in our database. You can also find out about relevant Cambrex Drugs and Medications on this site too.

Quick Search

Relevant Topic

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...

Corporate Database Quicklinks

Searches Linking to this Company Record